Evidence map›Paper›PMID 9687531›Full record

ArticleThe Journal of experimental medicine1998

Transendothelial migration of megakaryocytes in response to stromal cell-derived factor 1 (SDF-1) enhances platelet formation.

T Hamada, R Möhle, J Hesselgesser, J Hoxie, R L Nachman, M A Moore, S Rafii

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of experimental medicine, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers.

0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed
9.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

68 citing papers in PubMed, 245 citations in OpenAlex.

  1. Chemotherapy-induced thrombocytopenia: from "platelet counting" to ecological repair of the bone marrow.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Review
  2. Article
  3. Article
  4. Production of plateletsHaematologica · 2025
    Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. CXCR4eLife · 2022
    Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. New Insights Into the Differentiation of Megakaryocytes From Hematopoietic Progenitors.Arteriosclerosis, thrombosis, and vascular biology · 2019
    Review
  20. Megakaryocytes as immune cells.Journal of leukocyte biology · 2019
    Review

8 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 2 countries.

T HamadaDivision of Hematology-Oncology, Cornell University Medical College, New York 10021, USA.
R Möhle
J Hesselgesser
J Hoxie
R L Nachman
M A Moore
S Rafii
Memorial Sloan Kettering Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
CHEMOKINE RECEPTORS AND ITP AND HIV THROMBOCYTOPER01HL061849 · NHLBI · WEILL MEDICAL COLLEGE OF CORNELL UNIV · PI RAFII, SHAHIN · 1998 to 2002
$1.2M
ENDOTHELIUM REGULATION OF STEM CELL HOMING/PROLIFERATIONR01HL058707 · NHLBI · WEILL MEDICAL COLLEGE OF CORNELL UNIV · PI RAFII, SHAHIN · 1997 to 2000
$290k
NCI NIH HHS CA-08748NCI NIH HHS P30 CA008748NHLBI NIH HHS R01 HL061849NHLBI NIH HHS R01-HL-58707-01NHLBI NIH HHS R01-HL-61849-01
6 · The paper itself

Abstract

Although thrombopoietin has been shown to promote megakaryocyte (MK) proliferation and maturation, the exact mechanism and site of platelet formation are not well defined. Studies have shown that MKs may transmigrate through bone marrow endothelial cells (BMEC), and release platelets within the sinusoidal space or lung capillaries. In search for chemotactic factor(s) that may mediate transmigration of MKs, we have discovered that mature polyploid MKs express the G protein-coupled chemokine receptor CXCR4 (Fusin, LESTR). Therefore, we explored the possibility that stromal cell-derived factor 1 (SDF-1), the ligand for CXCR4, may also induce transendothelial migration of mature MKs. SDF-1, but not other CXC or CC chemokines, was able to mediate MK migration (ED50 = 125 pmol/liter). The MK chemotaxis induced by SDF-1 was inhibited by the CXCR4-specific mAb (12G5) and by pertussis toxin, demonstrating that signaling via the G protein-coupled receptor CXCR4 was necessary for migration. SDF-1 also induced MKs to migrate through confluent monolayers of BMEC by increasing the affinity of MKs for BMEC. Activation of BMEC with interleukin 1beta resulted in a threefold increase in the migration of MKs in response to SDF-1. Neutralizing mAb to the endothelial-specific adhesion molecule E-selectin blocked the migration of MKs by 50%, suggesting that cellular interaction of MKs with BMEC is critical for the migration of MKs. Light microscopy and ploidy determination of transmigrated MKs demonstrated predominance of polyploid MKs. Virtually all platelets generated in the lower chamber also expressed CXCR4. Platelets formed in the lower chamber were functional and expressed P-selectin (CD62P) in response to thrombin stimulation. Electron microscopy of the cells that transmigrated through the BMEC monolayers in response to SDF-1 demonstrated the presence of intact polyploid MKs as well as MKs in the process of platelet formation. These results suggest that SDF-1 is a potent chemotactic factor for mature MKs. Expression of CXCR4 may be the critical cellular signal for transmigration of MKs and platelet formation.

Indexed as

Blood PlateletsBone MarrowCell LineChemokine CXCL12Chemokines, CXCChemotaxisEndothelium, VascularHumansMegakaryocytesPolyploidyReceptors, CXCR4Chemokine CXCL12Chemokines, CXCCXCL12 protein, humanReceptors, CXCR4

Identifiers

PMID9687531
PMCPMC2212480
OpenAlexW2132274201

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.